Rocket Pharmaceuticals Inc RCKT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Rocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference
Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar
Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital
Rocket Pharma Shares Climb Premarket After FDA Supports Continuation of Trial
Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
Rocket Receives FDA Approval for Genetic Immunodeficiency Treatment
Trading Information
- Previous Close Price
- $2.16
- Day Range
- $2.03–2.20
- 52-Week Range
- $2.03–5.45
- Bid/Ask
- $2.00 / $2.11
- Shares Outstanding
- 111.66M
- Market Cap
- $235.60M
- Volume/Avg
- 2M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 202
- Website
- https://www.rocketpharma.com
Valuation
Metric | RCKT |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.72 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | RCKT |
|---|---|
Quick Ratio | 7.03 |
Current Ratio | 7.26 |
Interest Coverage | −6.43 |
Quick Ratio
RCKT
Profitability
Metric | RCKT |
|---|---|
Return on Assets (Normalized) | −45.18% |
Return on Equity (Normalized) | −54.13% |
Return on Invested Capital (Normalized) | −50.54% |
Return on Assets
RCKT
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|y>D$tt | LOCK|QW?d | $135B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|z&@ff^T | LOCK|>$Z$< | $99B | |||
| Moderna Inc MRNA | LOCK|JN#@>w@ | LOCK|Y% | $84B | |||
| argenx SE ADR ARGX | LOCK|Y^Q&$^ | LOCK|N@c | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|%>>%#m | LOCK|><> | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|pT&h%V$ | LOCK|<y&<X | $31B | |||
| Incyte Corp INCY | LOCK|H^&B?Q | LOCK|P< | $24B | |||
| BioNTech SE ADR BNTX | LOCK|?#vs^^h | LOCK|bn | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|QLdpY?y | LOCK|s#^? | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|^>%@TNB | LOCK|DWX | $15B |